Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of tesamorelin 2 mg in HIV patients with excess abdominal fat
2007-003233-16Phase 3Active
- Sponsor
- Theratechnologies Inc.
- Start
- Jul 2007
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HIV-associated lipodystrophy (HALS) and lipodystrophy comparing Tesamorelin 2 mg daily with Placebo (2 arms). Primary endpoints: Safety parameters and Duration of effect on visceral adipose tissue (VAT), trunk fat, and lipid profile. Started Jul 2007; status: active.
02
Drugs
tesamorelin
03
Conditions
HIV-associated lipodystrophy (HALS)lipodystrophy
Beyond the preview
Go deeper on 2007-003233-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003233-16.